In Brief: Interpore
This article was originally published in The Gray Sheet
Executive Summary
Interpore: Receives FDA go-ahead to commence a 20-patient pilot study of its Pro Osteon Implant 500 "as an autograft donor site backfill material." Slated to begin in the third quarter, the trial will evaluate the product's "impact on reducing pain and healing time" in lumbar spine fusion procedures, "where bone material harvested from the patient's iliac crest is used at the spinal fusion site." Ten patients in the study will receive Pro Osteon; 10 patients will receive autograft treatment without Pro Osteon...